PT-141 Dosage Guide: Chart & Protocol

PT-141 activates melanocortin-4 receptors in the hypothalamus, the brain region that controls arousal, appetite, and stress response. This is a fundamentally different mechanism from PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil), which work by increasing blood flow to the genitals.

The distinction matters because PT-141 works for people who do not respond to Viagra or Cialis. If the issue is desire (wanting sexual activity) rather than mechanics (blood flow), PT-141 addresses the root cause. PDE5 inhibitors improve erection quality but do nothing for desire.

PT-141 was derived from Melanotan II, a peptide originally developed for sunless tanning by researchers at the University of Arizona. When Phase 1 participants reported spontaneous arousal, Palatin Technologies isolated the MC4R-selective fragment and developed it as bremelanotide. The downstream signaling triggers dopamine and oxytocin release from the paraventricular nucleus (PVN) and medial preoptic area (MPOA), directly stimulating the neural circuits responsible for sexual motivation.

Pharmacokinetics. Subcutaneous bioavailability is approximately 100%. Time to peak plasma concentration (Tmax) is about 1 hour. Terminal half-life is 2.7 hours (range 1.9-4.0 hours) per FDA labeling and Diamond et al. (2004, PMID: 14963471). Despite the short half-life, effects on desire persist 6-72 hours due to sustained receptor activation.

For more on peptides that affect sexual function, see our libido and sexual health guide.

The 1.75 mg dose is the established standard. Going higher does not proportionally increase efficacy but does increase side effects, particularly nausea. Research consistently shows diminishing returns above 2.0 mg.

PT-141 is commonly available as a lyophilized (freeze-dried) powder in vials of 10 mg. Reconstitution requires bacteriostatic water.

Using 2 mL of bacteriostatic water is recommended for easier measurement on a standard insulin syringe. At 5 mg/mL concentration, 35 units on a U-100 insulin syringe delivers exactly 1.75 mg.

For a 1.5 mg dose: 30 units (0.30 mL) at 5 mg/mL concentration. For a 1.0 mg dose: 20 units (0.20 mL) at 5 mg/mL concentration.

Reconstituted PT-141 should be refrigerated and used within 28 days. Use our reconstitution calculator for custom calculations.

PT-141 has a longer onset and much longer duration than PDE5 inhibitors.

The wide duration range (6 to 72 hours) reflects significant individual variation. Most users report peak effects lasting 4 to 8 hours, with residual effects (increased sensitivity, enhanced desire) persisting for 24 to 48 hours. Some individuals report effects lasting up to 72 hours after a single dose.

The practical implication: PT-141 does not produce an instant, time-limited effect like Viagra. It creates a sustained state of enhanced desire that can last well beyond a single encounter. This is both an advantage (flexibility) and a consideration (plan accordingly).

PT-141 nasal spray is available from compounding pharmacies but was rejected by the FDA for good reason. Diamond et al. (2004, PMID: 14963471) studied intranasal bremelanotide and found significant variability in blood pressure response, which led the FDA to approve only the subcutaneous route.

The intranasal route requires significantly higher doses (7+ mg in the Diamond study) to achieve the same erectile response as 1.75 mg subcutaneous. This higher dosing increases systemic exposure and blood pressure variability. For users who strongly prefer avoiding injections, nasal spray is an option, but with less reliable dosing and no FDA safety data at compounded concentrations.

The keyword "pt-141 dosage bodybuilding" reflects a common misconception. PT-141 is not a performance-enhancing peptide. It does not build muscle, burn fat, or improve athletic performance.

The bodybuilding connection is historical. PT-141 was discovered through Melanotan II tanning research. Bodybuilders used Melanotan II for competition tanning and noticed the sexual arousal side effect. When PT-141 was isolated as the arousal-specific fragment, bodybuilding communities adopted it for a specific purpose: libido support during anabolic steroid cycles.

Testosterone suppression from anabolic steroid use commonly causes low libido. PDE5 inhibitors like Viagra fix erection mechanics but do nothing for desire. PT-141 addresses the desire component directly through MC4R activation, making it useful when exogenous testosterone has not fully restored sexual motivation.

The dosing protocol in bodybuilding contexts is identical to standard use: 1.75 mg subcutaneous, 45-60 minutes before activity, no more than 2-3 times per week. There is no "bodybuilding-specific" dose.

PT-141 is not prohibited by WADA. Unlike Melanotan II, which affects multiple melanocortin receptors including those involved in appetite regulation, PT-141's selective MC4R activity does not confer any competitive advantage.

Nausea is the dominant side effect, affecting up to 40% of first-time users. Data from the RECONNECT Phase 3 trials (Kingsberg et al., 2019, PMID: 31599840, n=1,267):

Structured nausea management protocol: 1. Start at 1 mg (not 1.75 mg) for first 2 uses to establish tolerance. 2. Take ondansetron (Zofran) 4-8 mg 30 minutes before PT-141 injection. 3. Eat a light meal 1-2 hours before (not immediately before). 4. Stay hydrated throughout. 5. Nausea typically diminishes after the first 2-3 uses as the body adjusts. 6. Optional: BPC-157 250-500 mcg 30-60 minutes before (gastroprotective properties; anecdotal support only).

Receptor desensitization warning. Using PT-141 more than 2-3 times per week can lead to melanocortin receptor desensitization, reducing effectiveness over time. The FDA's 8-dose monthly limit partially addresses this. Space doses at least 48-72 hours apart for optimal response.

Blood pressure warning. PT-141 causes temporary blood pressure elevation (5-10 mmHg systolic). Contraindicated in patients with uncontrolled hypertension. The RECONNECT trials excluded these patients for safety.

Skin hyperpigmentation. Because PT-141 retains some MC1R activity (the tanning receptor), rare cases of darkened moles, freckles, or gums have been reported with repeated use. Much less common than with Melanotan II, but not completely eliminated. Limiting use to 8 doses per month minimizes this risk.

Contraindications: Uncontrolled hypertension, concurrent naltrexone use, pregnancy/breastfeeding, hepatic impairment.

PT-141 is not a replacement for Viagra or Cialis. It addresses a different problem. PDE5 inhibitors fix the mechanical aspect (blood flow). PT-141 fixes the desire aspect (wanting sexual activity). Some practitioners combine both for patients with both desire and mechanical issues.

The injection requirement is the main barrier. Most patients prefer taking a pill to administering a subcutaneous injection. This is the primary reason PT-141 has not captured a larger market share despite its unique mechanism.